Cerebral palsy-the most common physical disability of childhood-is a clinical diagnosis encompassing a heterogeneous group of neurodevelopmental disorders that cause impairments of movement and posture that persist throughout life. Despite being commonly attributed to a range of environmental factors, particularly birth asphyxia, the specifi c cause of cerebral palsy remains unknown in most individuals. A growing body of evidence suggests that cerebral palsy is probably caused by multiple genetic factors, similar to other neurodevelopmental disorders such as autism and intellectual disability. Recent advances in next-generation sequencing technologies have made possible rapid and cost-eff ective sequencing of the entire human genome. Novel cerebral palsy genes will probably be identifi ed as more researchers and clinicians use this approach to study individuals with undiagnosed neurological disorders. As our knowledge of the underlying patho physiological mechanisms of cerebral palsy increases, so will the possibility of developing genomically guided therapeutic interventions.
Introduction
The fi rst description of cerebral palsy as a clinical entity is attributed to William John Little, an eminent British orthopaedic surgeon. In 1861, he wrote a monograph in which he proposed for the fi rst time an association between perinatal asphyxia and poor neurological outcomes later in life.
1 Three decades later, Sigmund Freud, a neurologist and founder of psychoanalysis, questioned Little's conclusions on the cause of cerebral palsy. On the basis of the observation that children with cerebral palsy had medical comorbidities, including intellectual disability, epilepsy, and visual disturbances, he proposed that cerebral palsy could begin earlier in life, during in-utero brain development.
2 Despite Freud's hypothesis, the notion that complications during labour and delivery are the leading cause of cerebral palsy was widely accepted by the medical, scientifi c, and lay communities. Not until almost one century later did large population-based studies show that only a minority of cerebral palsy cases result from birth asphyxia, thus providing support for Freud's hypothesis. [3] [4] [5] [6] Cerebral palsy is a clinical descriptive term applied to a heterogeneous group of neurodevelopmental disorders in which motor impairments often co-occur with a range of medical disorders. In 2004, the International Working Group on the Defi nition and Classifi cation of Cerebral Palsy 7 defi ned cerebral palsy as "a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cognition, communication, and behaviour; by epilepsy, and by secondary musculoskeletal problems". Unfortunately, in some cases, once a child is given a clinical diagnosis of cerebral palsy, limited eff orts, if any, are made to determine the underlying cause. However, identifi cation of specifi c causes of the disorder would provide individuals with cerebral palsy and their families with numerous benefi ts, including a better understanding of the disorder, accurate assessment of recurrence risk, and early intervention; it would also encourage further research into the development of specifi c medical treatments and therapeutic interventions for cerebral palsy.
Here, we review the growing body of evidence supporting the contribution of genetic abnormalities to cerebral palsy. We discuss previously proposed environmental risk factors and their eff ects on obstetric management and medical malpractice litigation. We also present an overview of the rapidly changing fi eld of cerebral palsy genetics, from the initial targeted association studies, which had inconclusive results, to the successful implementation of genome-wide, exon-level, copy-number array analyses and whole-exome sequencing that have enabled discovery of novel cerebral palsy genes and syndromes. Finally, we provide our perspective on present diagnostic challenges and directions for future research.
Epidemiology and classifi cation
Cerebral palsy is the most common cause of physical disability in childhood. 8 The worldwide prevalence of cerebral palsy has remained stable at 2-3 per 1000 livebirths for more than four decades, 9 despite substantial improvements in obstetric and neonatal care. A recent report from the Centers for Disease Control and Prevention 8 noted a prevalence of 3·3 per 1000 8-year-old children from four areas of the USA. Moreover, up to an estimated 1 million children and adults in the USA live with a diagnosis of cerebral palsy, with an average lifetime cost per aff ected individual in 2003 of US$921 000.
10,11 Because of the increasing life expectancy of individuals with cerebral palsy, the number of adults with this disorder is increasing and their medical and social care needs are changing.
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and neurological examination can help to identify abnormal neuromuscular tone (hypotonia or hypertonia) and the predominant type of motor impairment, which can be spastic, ataxic, dyskinetic (dystonia or choreoathetosis), or mixed. The characteristics and severity of the motor impairments should be described for each limb and the trunk to diff erentiate unilateral from bilateral involvement and to establish an anatomical distribution (monoplegia, diplegia, triplegia, hemiplegia, and tetraplegia). 13 These classifi cation systems, which are based on motor type and topography, are often used to infer which area of the brain might be aff ected (pyramidal or extrapyramidal systems); however, they have poor reliability, even among experienced clinicians. 14, 15 In an eff ort to establish an accurate, reliable, and standardised system to classify cerebral palsy, Palisano and colleagues 16 developed the gross motor function classifi cation system (GMFCS), a fi ve-level classifi cation based on the child's gross motor abilities, functional limitations, and need for wheeled mobility or assistive devices. 16 The GMFCS has been successfully implemented worldwide in a range of settings including routine clinical management (mobility assessment, intervention planning, and prognosis), research (sample selection and stratifi cation), and health-care admin istration. [17] [18] [19] A similar scale to assess bimanual fi ne motor function has been developed and validated as a complement to the GMFCS, 20, 21 and a manual ability classifi cation system has been designed to assess the ability of children with cerebral palsy to use their hands for routine activities. 22 Furthermore, the communication function classifi cation system was recently developed in an eff ort to assess the functional communication competence of individuals with cerebral palsy in daily life situations. 23 The development of objective and valid functional classifi cation systems has greatly improved health-care delivery and standardised research eff orts. 16, 18 Although the hallmark feature of cerebral palsy is motor and posture defi cit, patients often present with several other impairments and medical disorders. Commonly reported comorbidities include intellectual disabilities in 30-65%, seizure disorders in 30-50%, speech and language defi cits in 40%, visual impairments in 40%, and hearing problems in 5-15% of patients. [24] [25] [26] [27] [28] Additional systems that might be aff ected include the somatosensory (defi cits in stereognosis and proprioception), 29 genitourinary (enuresis, urinary infections, and voiding dysfunction), 30, 31 gastrointestinal (dysphagia, gastroesophageal refl ux disease, and constipation), 32 respiratory (recurrent pneumonia, atelectasis, bronchiectasis, and restrictive lung disease), 32 and endocrine systems (reduced growth and osteopenia). 33, 34 Furthermore, 20% of individuals with cerebral palsy have psychosocial and behavioural problems and 9% have an autism spectrum disorder. 35 The severity of the motor impairment, along with the presence and extent of accompanying disorders, infl uences the functional ability of individuals with cerebral palsy and also aff ects the burden and challenges faced by caregivers and the health system.
Causes
The causes of cerebral palsy have been attributed to a wide range of prenatal, perinatal, and postnatal factors that can present as single, isolated factors or as a combination of multiple potential risk factors. The presence and contribution of individual events varies to some extent between gestational groups and cerebral palsy subtypes. 36 The most commonly reported risk factors include prematurity, low birthweight, birth asphyxia, fetal intrauterine exposure to maternal infection and infl ammation, maternal fever during labour, multiple gestations, coagulation disorders and ischaemic stroke in the fetus or newborn, maternal thyroid disease, and placental pathology. [37] [38] [39] However, despite the large number of known and proposed causes, the specifi c causal mechanism remains elusive in most cases of cerebral palsy.
Perhaps the most studied, and still controversial, risk factor associated with cerebral palsy is birth asphyxia. Historically, and unfortunately still today in many groups (eg, researchers, clinicians, and the general public), inadequate oxygen delivery to the brain, caused by adverse intrapartum events, is assumed to be the leading cause of cerebral palsy. [40] [41] [42] On the basis of this hypothesis, detection and early intervention in episodes of acute birth asphyxia were proposed as ways to decrease the rate of cerebral palsy and improve long-term neurological outcomes of newborns at risk. 43, 44 To that extent, technologies such as electronic fetal monitoring during birth were developed and rapidly introduced into clinical practice, without adequate supporting evidence from scientifi c studies. 43, 44 Electronic fetal monitoring, considered a standard of care by many physicians and institutions, is now widely used to detect early fetal distress resulting from hypoxia during delivery, and despite a fi ve-times increase in the rate of caesarean sections, driven partly by the use of electronic fetal monitoring, 8 the incidence of cerebral palsy has not decreased over time. 9, 45, 46 Moreover, large population-based, controlled studies, done in various countries, over diff erent timeframes, and across diff erent populations, have shown that birth asphyxia is an uncommon cause of neonatal encephalopathy and accounts for less than 10% of cerebral palsy cases.
3,5, [47] [48] [49] [50] Even though most cases of cerebral palsy are not caused by birth asphyxia and those that are can rarely be prevented by obstetric intervention, 51 between 1999 and 2003 an estimated 76% of obstetricians in the USA faced medical malpractice litigation, most often for alleged birth mismanagement resulting in cerebral palsy. 44 A similar situation was reported in a 2002 study from Australia, which reported that 18% of the total medical indemnity claims were attributed to the 2% of physicians who practise obstetrics.
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In an eff ort to help clinicians, researchers, and law courts to identify whether an acute intrapartum event was probably the cause of any particular case of cerebral palsy, an objective template of evidence was published by the International Cerebral Palsy Task Force. 53 These guidelines, which are endorsed by multiple medical colleges and societies worldwide, provide three essential and fi ve non-essential criteria to defi ne an acute intrapartum hypoxic event (panel). The absence of any of the essential criteria strongly suggests that intrapartum hypoxia was not the cause of cerebral palsy.
An alternative hypothesis is that cerebral palsy is caused by many diverse and individually rare genomic abnormalities, as with other developmental brain disorders such as intellectual disabilities, 54 autism spectrum disorders, 55 and epilepsy. 56 However, as opposed to other neurodevelopmental disabilities, the contribution of genomic abnormalities to the occurrence of cerebral palsy has not been researched extensively, although in the authors' opinion it probably accounts for a substantial proportion of the 70-80% of cases that are attributed to prenatal causes. Furthermore, genomic abnormalities could also be the underlying cause in cases in which classic risk factors such as prematurity, coagulopathies, or diffi cult birth are identifi ed. 57 Children with malformations of cortical development present with birth complications more frequently than those without these malformations, which often results in the misdiagnosis of intrapartum asphyxia.
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Evidence for genetic factors in cerebral palsy
Several lines of evidence support the theory that multiple genetic factors contribute to the cause of cerebral palsy. First, mutations in multiple genes result in mendelian disorders that present with cerebral palsy-like features (as discussed below), and several single-gene mutations have been identifi ed in idiopathic (ie, non-syndromic) cerebral palsy pedigrees. [59] [60] [61] [62] [63] Second, the prevalence of congenital anomalies in individuals with cerebral palsy (11-32%) is signifi cantly higher than in the general population (2-3%). 64, 65 Most malformations in children with cerebral palsy are cerebral (72%), of which microcephaly (26%) and hydrocephaly (19%) are the most common. 64 Among the non-cerebral malformations, the most frequent are cardiac (29%), musculo skeletal (14%), and urinary abnormalities (9%), and facial clefts (18%). 64, 66, 67 Third, register-based studies have reported a signifi cantly higher concordance rate for cerebral palsy in monozygotic twins than in dizygotic twin pairs (p=0·0026). 68 Fourth, the risk of cerebral palsy in consanguineous families is about 2·5 times higher than the risk in outbred families. 69, 70 Fifth, several studies have reported familial aggregation of cerebral palsy, including identical cerebral palsy syndromes in the same family. [71] [72] [73] [74] [75] Sixth, a paternal age eff ect has been described in some forms of cerebral palsy. 76 Furthermore, a quantitative analysis of risk factors in 681 individuals with congenital cerebral palsy, from the west Swedish population-based cerebral palsy study, estimated that 60% of hemiplegic cerebral palsy cases, 45% of spastic diplegic cases, and an estimated 100% of cases with isolated ataxia, were caused by genetic mutations. 77 The mathematical method used for this study, which was based on medical history analysis of prenatal and perinatal risk factors, has been previously validated and successfully applied for the study of individuals with intellectual disabilities. 78 Despite the growing body of evidence for genomic causes of cerebral palsy, it has traditionally been proposed that genetic and metabolic abnormalities should be ruled out before a diagnosis of cerebral palsy is made. 79 However, comprehensive genetic testing is rarely, if ever, off ered as part of the diagnostic workup of individuals with suspected cerebral palsy, which makes cerebral palsy gene discovery a challenging task. Furthermore, in several studies in which individuals with cerebral palsy were found to harbour genetic mutations, the diagnosis was often changed and cerebral palsy was regarded as an initial misdiagnosis. 80 At present, our knowledge of the genomic component of cerebral palsy lags behind that of other neurodevelopmental disorders, such as intellectual disabilities and autism spectrum disorders.
The cerebral palsy spectrum disorders
Cerebral palsy is a non-specifi c clinical diagnosis made on the basis of the presence of signs and symptoms, such as delayed motor development and abnormalities in posture, muscle tone, coordination, and refl exes. Thus, it is not uncommon for individuals with a wide range of neurodevelopmental conditions to be Criteria that together suggest an intrapartum timing but by themselves are non specifi c 4 A sentinel (signal) hypoxic event occurring immediately before or during labour 5 A sudden, rapid, and sustained deterioration of the fetal heart rate pattern, usually after the hypoxic sentinel event, where the pattern was previously normal 6 Apgar scores of 0-6 for longer than 5 min 7 Early evidence of multisystem involvement 8 Early imaging evidence of acute cerebral abnormality Review diagnosed with cerebral palsy. 81 Several single-gene (mendelian) disorders, inherited as autosomal dominant, autosomal recessive, or X-linked, often present with clinical features similar to cerebral palsy (webappendix). In such cases, individuals might live with a diagnosis of cerebral palsy for several years before specifi c molecular or biochemical diagnostic testing is done. Some of these mendelian disorders are individually rare, but as a group they are not uncommon and should all be considered when assessing an individual with cerebral palsy. Moreover, the spectrum of cerebral palsy-like syndromes includes some genetic conditions that, once identifi ed, can be successfully treated with available drugs.
Of particular interest, because of the potential for genomically guided therapeutic interventions, is the group of dopa-responsive dystonic disorders caused by mutations in the GCH1 (GTP cyclohydrolase 1), SPR (sepiapterin reductase), and TH (tyrosine hydroxylase) genes. 82 If untreated, individuals with these disorders can progress to a state of complete loss of ambulation, whereas appropriate management with levodopa results in a dramatic and sustained improvement in symptoms, even in advanced cases. 83 Recently, Lee and colleagues 84 reported the case of a severely disabled young woman who presented with bilateral club foot, stiff ness of the trunk, neck, and arms, and an inability to walk. She had lived with a diagnosis of cerebral palsy for more than 10 years until a small dose of levodopa was prescribed and dramatically improved her condition, prompting further genetic testing. Sequencing of the GCH1 gene identifi ed a pathogenic mutation and a diagnosis of dopa-responsive dystonia was made. Because of shared clinical features, up to 24% of patients with dopa-responsive dystonia are initially diagnosed with cerebral palsy. 85 Furthermore, a recent report by Bainbridge and colleagues 86 described a twin pair with dopa-responsive dystonia of unknown cause (previously diagnosed as cerebral palsy), whose genomes were sequenced and found to contain compound heterozygous mutations in the SPR gene. Because disruption of this gene leads to a decrease in tetrahydrobiopterin (cofactor for the synthesis of dopamine and serotonin), their management with levodopa was supplemented with a serotonin precursor (oxitriptan), which resulted in symptomatic improvement after 1 week of treatment. These examples show the importance of undertaking comprehensive genetic testing in individuals with disorders of the cerebral palsy spectrum, and provide compelling evidence for genomically oriented medical decision making.
Another group of genomic diseases that often presents as cerebral palsy is the hereditary spastic paraplegias (HSP). These disorders are characterised by leg weakness and spasticity arising from length-dependent, distal axonopathy of the corticospinal tract fi bres. 87 More than 40 loci have been mapped for HSP, which can be inherited in an autosomal dominant, autosomal recessive, or X-linked fashion. 88 Rainier and colleagues 89 assessed a 34-year-old woman who had been diagnosed with spastic diplegic cerebral palsy in early childhood. When her 10-month-old child presented with similar symptoms, both mother and child were diagnosed with autosomal dominant, uncomplicated, early-onset HSP. Further genetic testing identifi ed a heterozygous mutation in the ATL1 (atlastin GTPase 1) gene, which is responsible for spastic paraplegia type 3A.
The webappendix summarises additional mendelian disorders that present with features of cerebral palsy, including recognisable genetic disorders such as Rett (MECP2) 90 and Angelman (UBE3A) syndromes; 91 metabolic disorders including Lesch-Nyhan syndrome (HPRT) 92 and glutaric acidemia type 1 (GCDH); 93 heritable thrombophilias, such as protein C defi ciency (PROC); 57 and cerebral dysgenesis such as classic lissencephaly (PAFAH1B1) 94 and pontocerebellar hypoplasia type 1 (VRK1). 
Single-gene causes of idiopathic cerebral palsy
As described below, the identifi cation of the fi rst cerebral palsy genes was accomplished by positional cloning techniques, such as microsatellite-based linkage mapping, followed by conventional (Sanger) sequencing of candidate genes in large multi-generational families with multiple aff ected individuals. 59 More recent studies have relied on high-resolution copy number variation analyses and next-generation sequencing technologies for gene discovery. [61] [62] [63] At the time of this Review, the total number of genes with mutations causing human disease was 2687, 96 of which six are known to cause mendelian forms of cerebral palsy (table 1) . [59] [60] [61] [62] [63] The list of monogenic causes of cerebral palsy will probably grow exponentially because of the increasing use of cutting-edge genomic technologies to assess individuals with undiagnosed disorders of brain development.
GAD1
In 2004, Lynex and colleagues 59 were the fi rst group to identify a gene linked to a mendelian form of cerebral palsy. They reported two consanguineous families in which six individuals presented with congenital spastic cerebral palsy of unknown cause. All individuals had global developmental delay, moderate-to-severe intellectual disability, poor or absent speech, and spasticity with hypertonia and brisk refl exes predominantly in the legs. One family member also had micro cephaly, contractures, and kyphoscoliosis, and another had bilaterally dislocated hips that needed surgical management. With 290 polymorphic DNA markers for linkage mapping, a 5 cM region of homozygosity was identifi ed on chromosome 2q24-q25 and subsequently refi ned to 0·5 cM by microsatellite typing. The region included the GAD1 gene, which encodes the brain-expressed isoform of glutamate decarboxylase, and See Online for webappendix Review was considered a good candidate gene for cerebral palsy by Lynex and colleagues. 59 Direct sequencing of GAD1 in aff ected and unaff ected individuals from both families revealed a homozygous missense mutation segregating with the cerebral palsy phenotype. Glutamate decarboxylase is responsible for the production of GABA, the major inhibitory neurotransmitter, from its excitatory counterpart glutamate. Both molecules, and the balance between excitatory and inhibitory neurotransmission, which is modulated partly by GAD1, are crucial for normal brain development and synaptic plasticity.
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KANK1
1 year after the discovery of the fi rst cerebral palsy gene, Lerer and colleagues 60 studied a large four-generation pedigree in which nine children had cerebral palsy. All aff ected individuals were born after normal pregnancies and showed congenital hypotonia that evolved to spastic tetraplegia within the fi rst year of life. Additional features included moderate-to-severe intellectual disability, nystagmus, and brain atrophy with ventriculomegaly. Linkage analysis showed that a region on chromosome 9p24.3 seemed to harbour the causative gene. Further studies identifi ed a 225 kb deletion on 9p24.3 involving one gene, KANK1 (KN motif and ankyrin repeat domains 1, previously called ANKRD15), in aff ected individuals in the family, which was not identifi ed in 210 control individuals. KANK1 is expressed in the developing brain and is thought to play a part in proteinprotein interactions and adhesion complexes. 60 Moreover, the KANK family of proteins regulates actin polymerisation and cell migration.
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The adaptor protein complex-4 defi ciency syndrome: AP4M1, AP4E1, AP4B1, and AP4S1
In 2009, Verkerk and colleagues 61 reported data from a consanguineous Moroccan family in which fi ve sib lings had cerebral palsy. They presented with infantile hypotonia that progressed to spastic tetraplegia with hypertonia and hyper-refl exia, severe intellectual disability, absent speech, and absence of independent walking and sphincter control. Additional features included microcephaly, drooling, and stereotypical laughter. Neuroimaging studies showed diff use white matter loss, ventriculomegaly, and cerebellar atrophy. Post-mortem neuropathological examination of a patient who died of aspiration pneumonia at 17 months revealed reduced myelin in cerebral white matter compared with normal brains and abnormal dendritic arborisation of cerebellar Purkinje cells compared with an age-matched control individual. Using homozygosity mapping followed by candidate gene sequencing, a homozygous mutation in the AP4M1 gene, encoding the μ subunit of the adaptor protein complex-4 (AP-4), was identifi ed in all aff ected individuals.
After this report, our group 62 reported a PalestinianJordanian inbred kindred with two siblings aff ected by a type of cerebral palsy that resembled that of the indi viduals previously described. 61 Both patients presented at birth with microcephaly and hypotonia that progressed to spastic tetraplegia with hyper-refl exia and generalised hypertonia. They also had severe intellectual disability, generalised tonic-clonic seizures, absent speech, an inability to walk or to control sphincters, drooling, and outbursts of stereotypical laughter. Dysmorphic features included bitemporal narrowing, down-slanted palpebral fi ssures, a broad nasal bridge, and a short philtrum. Brain MRI showed ventriculomegaly, cerebellar atrophy, reduced hippo campal volume, and white matter loss. We did copy number array analyses and identifi ed a homozygous deletion on chromosome 15q21.2 that included exons 1-11 of the AP4E1 (ε subunit of AP-4) gene in both individuals.
On the basis of fi ndings from these two unrelated cerebral palsy pedigrees, each of which had a homozygous mutation in a diff erent subunit of AP-4 (AP4E1 62 and AP4M1 61 ), along with previous fi ndings that mutations in a third subunit (the β subunit) result in axonal abnormalities in mice, 99 we proposed that disruption of any one of the four subunits of AP-4 (AP4E1, AP4M1, AP4B1, and AP4S1) would result in dysfunction of the entire complex and lead to a distinct autosomal recessive cerebral palsy disorder, which we defi ned as AP-4-defi ciency syndrome. 62 Our hypothesis was confi rmed by a recent study of eight individuals, from three consanguineous families, who presented with a similar phenotype to that described in the previous patients (summarised in table 2). 63 In addition to sharing many neurodevelopmental features, these individuals had common dysmorphisms, including a wide nasal bridge, bulbous nose, and coarse features. By autozygosity mapping followed by either sequencing of candidate genes or whole-exome sequencing, mutations in AP4E1, AP4B1 (β subunit of AP-4), and AP4S1 ( subunit of AP-4) were identifi ed in aff ected individuals from each of the three pedigrees. 63 Furthermore, a recent study of 136 consanguineous families with autosomal recessive intellectual disability identifi ed mutations in AP4E1 and AP4M1 in two unrelated families with fi ve individuals aff ected by severe intellectual disability, microcephaly, and spastic paraplegia. 100 These fi ndings from 20 aff ected individuals from seven unrelated consanguineous families provide Furthermore, because all aff ected individuals presented with a similar cerebral palsy phenotype, the existence of an AP-4-defi ciency syndrome is confi rmed, defi ning a clinically and genetically recognisable form of cerebral palsy.
The AP-4 complex
The adaptor protein complexes AP-1, AP-2, AP-3, and AP-4 are ubiquitously expressed heterotetrameric structures that play a crucial part in vesicular traffi cking of membrane proteins along the late secretory and endocytic pathways. 101 They create an interface between cargo molecules and an outer coat protein, thus promoting the assembly of coated vesicles. The AP complexes are composed of four diff erent subunits that come together to form a heterotetramer: one large variable subunit (γ in AP-1, α in AP-2, δ in AP-3, and ε in AP-4), one large subunit with high homology between the complexes (β1-4), one medium subunit (μ1-4), and one small subunit ( 1-4). 102 Although all four AP complexes share a common structural pattern, each one targets a diff erent set of cargo proteins to be included into coated vesicles and sorted along a specifi c traffi cking route.
The AP-4 complex is expressed in the CNS throughout the embryologic and postnatal developmental stages. 61, 103 It selectively sorts proteins from the trans-Golgi network to the postsynaptic somatodendritic domain, avoiding the presynaptic axonal domain, thus helping to establish neuronal polarity. 104 Known cargo molecules sorted by AP-4 include AMPA and δ2 glutamate receptors, transmembrane AMPA receptor regulatory proteins, low-density lipoprotein receptors, and Alzheimer's disease amyloid precursor protein (APP). 99, 103, 105 Because AMPA receptors participate in excitatory synaptic transmission, adequate AP-4-mediated traffi cking of these receptors to their target membrane is crucial for neurotransmission and synaptic plasticity. Moreover, AP-4-dependent transport of APP reduces γ secretase cleavage of the precursor protein to the pathogenic amyloid-β peptide. 105 Therefore, defi ciency of AP-4 has the potential to disturb crucial neurophysiological processes, leading to increased amyloidogenic processing of APP and abnormal synaptic transmission due to defi cient cycling of glutamate receptors.
In an eff ort to defi ne the role of AP-4 in neurons, Matsuda and colleagues 99 disrupted the gene encoding the β subunit of the complex in mice, both in vitro and in vivo. AP-4-defi cient mice showed no major brain anomalies but did less well on the rotorod test than wildtype mice. Furthermore, examination of cerebellar Purkinje cells and hippocampal neurons revealed axonal swelling and accumulation of AMPA, δ2, and low-density lipoprotein receptors in autophagosomes near the axon terminals. These fi ndings suggest that AP-4 defi ciency results in loss of somatodendritic-specifi c sorting of cargo molecules, leading to mislocalisation of such proteins to the axonal domain and further degradation via the autophagic pathway. Together, these fi ndings highlight the crucial role of vesicular traffi cking in brain development and function, and show how disturbances in diff erent proteins along a shared biological pathway can lead to disorders with similar clinical phenotypes. Furthermore, these fi ndings show that several genes and proteins involved in the AP-4-mediated vesicular traffi cking pathway are strong candidate genes for cerebral palsy. Further studies are needed to establish the frequency of AP-4-defi ciency syndrome and to explore the contribution of other genes in this pathway to the development of cerebral palsy.
Genetic association studies
On the basis of the hypotheses that abnormalities in the infl ammatory system and the coagulation cascade might contribute to the causal pathway of cerebral palsy, numerous studies have explored whether single nucleotide polymorphisms (SNPs) in a subset of genes involved in these processes confer an increased risk for cerebral palsy. Some of the most studied poly morphisms are located within genes that code for factor V Leiden, prothrombin, methylenetetrahydrofolate reductase, apo lipoprotein E (APOE ε2 and ε4 alleles), interleukins 6 and 8, nitric oxide synthase (endothelial and inducible), platelet activator inhibitor, endothelial protein C receptor, mannose binding lectin, tumour Review necrosis factor α, and lymphotoxin-α. 106 Despite more than 20 case-control studies focused on these candidate genes, the results are inconsistent and often confl icting. In an eff ort to increase the statistical power of individual studies, Wu and colleagues 107 undertook a meta-analysis exploring 17 polymorphisms in 2533 cases and 4432 control individuals from 11 studies and concluded that only one SNP in interleukin-6 (rs1800795) was signifi cantly associated with cerebral palsy. 107 In 2009, O'Callaghan and colleagues 108 applied the human genome epidemiology network (HuGENet) guidelines to undertake a systematic review of 22 targeted association studies in individuals with cerebral palsy. Multiple polymorphisms were analysed, including 18 SNPs in thrombophilic genes, eight in cytokine genes, APOE ε2, ε3, and ε4 alleles, and 23 polymorphisms in genes involved in other systems. The authors concluded that because of limited sample sizes, ethnically diverse cohorts, and inadequate control individuals in most studies, proposed associations of SNPs and cerebral palsy outcome remained controversial. 108 However, some candidate genes, including factor V Leiden, methylene tetrahydrofolate reductase, lymphotoxin-α, tumour necrosis factor-α, endothelial nitric oxide synthase, and mannose binding lectin, were more promising than the rest in O'Callaghan and colleagues' opinion. The most recent population-based, case-control study investigating genetic poly morphisms in cerebral palsy included 138 cases and 165 control individuals from 334 333 infants born at term or near term in a health-care organisation in California, USA. 106 In an eff ort to replicate previously proposed associations between genetic polymorphisms and cerebral palsy, 15 well studied SNPs were genotyped. After correcting for multiple comparisons, no statistically signifi cant association between any SNP and cerebral palsy was identifi ed.
Genetic association studies have failed to reach strong, replicable results when applied to complex, multi factorial, and highly heterogeneous groups of disorders, such as cerebral palsy. The genomic makeup of cerebral palsy probably resembles that of other developmental brain disorders that result from multiple rare, and often private (ie, mutations rare enough to be restricted to an individual or kindred), genetic variations that are infrequently detected in association studies. 55, 109 Further more, because all cerebral palsy association studies so far have been hypothesis driven, only a limited number of polymorphisms within a small group of candidate genes have been assessed. At present, commercially available genotyping platforms feature more than 1·5 million markers that can be used simultaneously for genome-wide association studies and copy number variation analyses. The imple mentation of whole-genome scans, as an unbiased approach to study individuals with cerebral palsy, could enable discovery of novel cerebral palsy genes and biological pathways to further unravel the genomic underpinnings of this disorder.
Whole-exome and genome sequencing
The longstanding quest to fi nd the cause of some of the most common neurodevelopmental disorders, as well as rare conditions with suspected genetic causes, has recently made rapid progress, with exciting new fi ndings. A major factor in this success comes from recent advances in next-generation sequencing tech nologies, which have allowed rapid and cost-eff ective sequencing of the entire human genome or a subset that includes all coding genes, referred to as the exome. 110 Exome sequencing has been successfully implemented to uncover the causative gene in a range of mendelian disorders, including MLL2 in Kabuki syndrome, 111 DHODH in Miller syndrome, 112 and KIF1A in hereditary spastic paraparesis. 113 Furthermore, the widespread use of trio-based exome sequencing as the standard approach to study complex neurodevelopmental disorders has resulted in the discovery of pathogenic de-novo mutations in multiple genes for intellectual disability, 114 autism spectrum disorders, 115 and schizophrenia. 116 These fi ndings support the notion that developmental brain disorders such as cerebral palsy are probably caused by hundreds of genes, and that systematic family-based exome or genome sequencing has the power to uncover them.
Conclusions
The fi eld of cerebral palsy genetics is rapidly growing and has already changed our understanding of the underpinnings of this complex disorder. Multiple monogenic syndromes that present with cerebral palsylike features (cerebral palsy spectrum disorders) should be considered as part of the diagnostic assessment of individuals with suspected cerebral palsy. Furthermore, we now know of six genes that can cause cerebral palsy when disrupted, and we estimate that many other develop mental brain genes probably contribute to the genetic heterogeneity of this disorder. The availability of personal and familybased genome sequencing has made identi fi cation of rare or private mutations in cerebral palsy families feasible at a reasonable cost-at present for research and soon on a clinical diagnostic basis. Moreover, the continuous discovery of genes and molecular pathways that are
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For HuGENet see http://www. cdc.gov/genomics/hugenet/ Review disrupted in cerebral palsy will increase the possibility of developing genomically guided pharma cological interventions for this disorder. As the paradigm shift continues and more researchers, clinicians, and the general population start to consider the cerebral palsies as a group of neurogenetic disorders, we will probably witness an increase in research eff orts, a change in the diagnostic approach, and eventually novel therapies for cerebral palsy. This exciting new era of cerebral palsy genomics will unquestionably benefi t this patient population.
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